

AASLD-Recommended HCV Treatments: DAA-Naive Patients

HCV Genotype	No Cirrhosis		Compensated Cirrhosis		eGFR < 30 mL/min	
	Regimen	Treatment Duration	Regimen	Treatment Duration	Regimen	Treatment Duration
1	SOF/LDV,* GLE/PIB	8 wks			GLE/PIB [¶]	8 wks
	GRZ/ELB, [†] SOF/VEL	12 wks	GLE/PIB, GRZ/ELB, [†] SOF/LDV, [§] SOF/VEL	12 wks	GRZ/ELB	12 wks
2	GLE/PIB	8 wks			GLE/PIB [¶]	8 wks
	SOF/VEL	12 wks	GLE/PIB, SOF/VEL	12 wks		
3	GLE/PIB [§]	8 wks			GLE/PIB ^{¶,§}	8 wks
	SOF/VEL	12 wks	GLE/PIB, [§] GRZ/ELB + SOF, [‡] SOF/VEL, ^{§#} SOF/VEL/VOX [‡]	12 wks		
4	GLE/PIB	8 wks			GLE/PIB [¶]	8 wks
	GRZ/ELB, [¶] SOF/VEL, SOF/LDV	12 wks	GLE/PIB, GRZ/ELB, [¶] SOF/LDV, [§] SOF/VEL	12 wks	GRZ/ELB	12 wks
5, 6	GLE/PIB	8 wks			GLE/PIB [¶]	8 wks
	SOF/LDV, SOF/VEL	12 wks	GLE/PIB, SOF/LDV, SOF/VEL	12 wks		

*If pegIFN/RBV naive, nonblack, no HIV, and HCV RNA < 6 million IU/mL. Otherwise, increase to 12 weeks.

[†]Not recommended if both genotype 1a and baseline NS5A resistance for ELB detected. [‡]Not recommended if pegIFN/RBV naive. [§]Not recommended if pegIFN/RBV experienced. [¶]If pegIFN/RBV experienced, must have experienced virologic relapse after pegIFN/RBV. [¶]If also cirrhotic, increase to 12 weeks. [#]If baseline Y93H resistance-associated substitution present, add RBV or consider SOF/VEL/VOX.



CLINICAL CARE OPTIONS®
HEPATITIS

clinicaloptions.com/HCVUpdates2017

AASLD-Recommended HCV Treatments: DAA-Experienced Patients

HCV Genotype	NS3 + PegIFN/RBV Experience		Non-NS5A, SOF-Containing Experience		NS5A Experience	
	Regimen	Treatment Duration	Regimen	Treatment Duration	Regimen	Treatment Duration
1	GLE/PIB, SOF/LDV,* SOF/VEL	12 wks	GLE/PIB, SOF/VEL, [†] SOF/VEL/VOX [‡]	12 wks	SOF/VEL/VOX	12 wks
2			GLE/PIB, SOF/VEL	12 wks		
3	SOF/VEL/VOX [§]	12 wks	SOF/VEL/VOX [§]	12 wks	SOF/VEL/VOX [§]	12 wks
4, 5, 6	SOF/VEL/VOX	12 wks	SOF/VEL/VOX	12 wks	SOF/VEL/VOX	12 wks

*Not recommended if also cirrhotic. [†]Not recommended if genotype 1a. [‡]Not recommended if genotype 1b. [§]If also cirrhotic and prior NS5A failure, add RBV.

AASLD, American Association for the Study of Liver Diseases; DAA, direct-acting antiviral; eGFR, estimated glomerular filtration rate; ELB, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; LDV, ledipasvir; pegIFN, peginterferon; PIB, pibrentasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.

October 2017

Reference

AASLD/IDSA. HCV guidelines. September 2017.

Refer to www.hcvguidelines.org for full recommendations.